NOTTINGHAM, England, March 18, 2024 /PRNewswire/ -- Drug development and manufacturing accelerator Quotient Sciences has announced major changes to its commercial and scientific executive leadership team, strengthening its position as a global leader in the sector.
Quotient Sciences supports YourChoice Therapeutics with Phase I trial of novel hormone-free male birth control pill
Quotient Sciences supports Medivir with updated formulation of fostrox
Quotient Sciences Recognized in the Pharma Innovation Awards 2023
Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand
Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO
Quotient Sciences Announces Successful US FDA Inspection of Alnwick, UK Facility
Manufacturing Chemist: Paul Quigley on overcoming bio/pharmaceutical production hurdles
European Pharmaceutical Manufacturer: Catherine Wilkes on Achieving HPAPI Manufacturing Success
NOTTINGHAM, England, Sept. 21, 2023 /PRNewswire/ -- A drug development partnership between Evecxia Therapeutics and Quotient Sciences has resulted in the successful delivery of a Phase 1 clinical testing program for Evecxia's drug candidate EVX-101, which is in development for major depressive disorder (MDD).